Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction
NCT ID: NCT03394911
Last Updated: 2020-10-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
500 participants
INTERVENTIONAL
2020-12-31
2021-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oxytocin Treatment of Alcohol Dependence
NCT02275611
Oxytocin Treatment of Alcohol Withdrawal
NCT01212185
Oxytocin Treatment of Alcohol Dependence
NCT02251912
Efficacy and Tolerability of Baclofen for Alcohol Dependence
NCT00877734
The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program
NCT02431728
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To mitigate aversive airborne sub-pheromone methyl esters (almost certainly the cause of artificial aversive emotions), we will be trying several attenuation strategies. Staff collecting, storing, and dispensing pheromone (and placebo) will utilize the provided 3M Versaflo supplied air carbon filtered respirator for pharmaceutical applications. Collection from volunteer pheromone donors and administration to tox screened opioid addicts will be in areas ventilated by Dyson carbon-filtered oscillating fans placed to break up plumes of airborne sub-pheromone sufficiently to attenuate aversive emotion. Other lab techniques will also be tried as artificially stimulated emotional and heartfelt complaints are expected, from everybody. Unfortunately, the rapid process of healing opioid addiction will involve the unavoidable creation of potentially problematic emotions. We will try smaller daily doses, reverse Fisher esterification with apple cider vinegar, more vigorous air disturbances, negative air pressure, fume hoods, isolation, etc.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental Group
250mg p.o. of healthy adult male facial skin surface lipid liquid pheromone on fresh, new, just-purchased, un-chewed Wrigley's Rain #5 sugarless chewing gum vehicle. 15 pieces or divided as tolerated.
250mg healthy adult male facial skin surface lipid liquid pheromone
Human Pheromone provided p.o. to tox-screen verified opioid drug addict
Placebo Group
Placebo identical to Experimental dose with randomly assigned identification numbers on unopened, unsealed key. Placebo and Experimental doses kept together and undifferentiable without the key being opened. Key available for opening 24/7 w/pharmaceuticals tech onsite. Keep pheromone/placebo doses under a fume hood. Wear 3M Versaflo activated charcoal filter supplied air respirator or equivalent to access.
250mg healthy adult male facial skin surface lipid liquid pheromone
Human Pheromone provided p.o. to tox-screen verified opioid drug addict
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
250mg healthy adult male facial skin surface lipid liquid pheromone
Human Pheromone provided p.o. to tox-screen verified opioid drug addict
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tampa General Hospital
OTHER
Otrimed Clinical Research
OTHER
Bubba Nicholson
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bubba Nicholson
Senior Scientist in Charge
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ross C Nicholson, BsIMGT
Role: PRINCIPAL_INVESTIGATOR
Nicholson Science
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Nicholson B. Does kissing aid human bonding by semiochemical addiction? Br J Dermatol. 1984 Nov;111(5):623-7. doi: 10.1111/j.1365-2133.1984.tb06635.x. No abstract available.
Nicholson B. Pheromones cause disease: pheromone/odourant transduction. Med Hypotheses. 2001 Sep;57(3):361-77. doi: 10.1054/mehy.2001.1357.
Nicholson B. Pheromones cause disease: the exocrinology of anorexia nervosa. Med Hypotheses. 2000 Mar;54(3):438-43. doi: 10.1054/mehy.1999.0872.
Nicolaides N. Skin lipids: their biochemical uniqueness. Science. 1974 Oct 4;186(4158):19-26. doi: 10.1126/science.186.4158.19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.